Clinical trials: Human
NSCLC, Gastric Cancer
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with…
- Trial name
- NCT02563548
- Testing
- PEGPH20, Pembrolizumab
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Halozyme Therapeutics
Pharmacokinetics, Cytochrome P-450 CYP2D6
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects.
- Conditions
- Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
- Trial name
- NCT01188668
- Testing
- Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect…
- Trial name
- NCT00836888
- Testing
- ONO-4538
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Decision Making, Computer Aided Diagnosis
Project 3 Example: Human-AI Collaboration Tester (HAICT) Exp. 7
The study is one part of a "bundle" of experiments that constitute Project Three of a National Eye Institute grant. Project Three includes a series of experiments that investigate how changing the input from a simulated AI can…
- Trial name
- NCT05272189
- Testing
- Simulated Second Reader AI, Target Prevalence
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
HIV Infections, Syphilis
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S.
- Trial name
- EHPOC (NCT04793750)
- Testing
- Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Influenza
Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women
The purpose of this research study is to learn more about the safety of 2 licensed flu vaccines, nasal spray and flu vaccine shot, in mothers and their infants, when given to women who are breastfeeding and to compare the immune…
- Trial name
- NCT01181323
- Testing
- Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
- Where
- 6 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Influenza
Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of a second vaccination with candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
- Trial name
- NCT00385840
- Testing
- Influenza Vaccine GSK1247446A, FluarixTM
- Where
- 4 sites in Norway
- Volunteers
- 678 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Influenza, Acute Respiratory Infection
FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths.
- Conditions
- Influenza, Acute Respiratory Infection, Influenza-like Illness
- Trial name
- NCT03274310
- Testing
- Educational text messages
- Where
- United States
- Volunteers
- 1,918 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hepatitis C Virus
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with…
- Trial name
- HEPCAT (NCT01170962)
- Testing
- BMS-790052, peginterferon alfa-2a, ribavirin
- Where
- 72 sites in United States, Argentina and 9 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
Influenza
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years
- Trial name
- NCT00374842
- Testing
- Fluarix™, GSK1247446A
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatomyositis
Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS
- Trial name
- NCT03686969
- Testing
- Octanorm
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Octapharma
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00509769
- Testing
- Trastuzumab emtansine [Kadcyla]
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Genentech, Inc.
Cardiac Transplant Disorder
Don't Throw Your Heart Away: Medical Student Study 2
Publicly available outcome assessments for transplant programs do not make salient that some programs tend to reject many of the hearts they are offered, whereas other programs accept a broader range of donor offers.
- Trial name
- NCT04176796
- Testing
- Stratified Transplant Survival
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Long Term Open Label Continuation Study
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
- Trial name
- NCT00195650
- Testing
- Adalimumab
- Where
- 92 sites in United States, Canada
- Volunteers
- 846 people
- Sponsor
- Abbott
Lactation
Recombinant Human Prolactin for Lactation Induction
The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).
- Trial name
- NCT00181623
- Testing
- Recombinant Human Prolactin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.
- Trial name
- STEALTHC-3 (NCT00637923)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 112 people
- Sponsor
- Romark Laboratories L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.